Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sino Biopharmaceutical ( (HK:1177) ) has shared an update.
Sino Biopharmaceutical announced that its subsidiary LaNova Medicines has enrolled the first patient in a Phase III registrational clinical trial of cafelkibart (LM-108), a CCR8 monoclonal antibody, as a second-line treatment for CCR8-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma in combination with a PD-1 inhibitor. This is the second pivotal registrational trial for LM-108, which has already received two Breakthrough Therapy Designations in China and is being positioned as a potential global first-in-class CCR8-targeted therapy.
Earlier Phase I/II data showed that LM-108 combined with toripalimab produced notable improvements in response rates, disease control and survival versus current paclitaxel-based standards, particularly in patients with higher CCR8 expression. By selectively eliminating immunosuppressive regulatory T cells in the tumor microenvironment and potentially overcoming resistance to existing immunotherapies, the program could significantly enhance Sino Biopharmaceutical’s standing in oncology and offer a novel treatment paradigm for second-line advanced gastric cancer and other MSI-H/dMMR solid tumors.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group focused on the research, development and commercialization of innovative medicines, particularly in oncology. Through wholly owned subsidiary LaNova Medicines, the company advances cutting-edge biologics, including monoclonal antibodies aimed at addressing high-incidence cancers in China and globally.
Average Trading Volume: 70,256,802
Technical Sentiment Signal: Buy
Current Market Cap: HK$97.92B
For an in-depth examination of 1177 stock, go to TipRanks’ Overview page.